Navigation Links
News from Molecular Medicine
Date:5/20/2010

Cystic Fibrosis (CF) continues to challenge scientists. There is growing evidence that increases in protease activity may be central to the pathogenesis of this lung disease. A team of scientists at the University of Alabama measured a common protease called MMP-9 in CF patients whose condition is stable and compared it with healthy volunteers. Previous studies have shown increases in MMP-9 in CF patients in the throes of an acute pulmonary episode. In the latest study, scientists at the University of Alabama in Birmingham reported that MMP-9 levels were also higher than normal in CF patients with no active airway inflammation. The findings may point the way to new therapeutic agents that work to reduce pathological changes.

Manhasset, NY (Vocus) May 20, 2010 -- In the latest issue of Molecular Medicine, cystic fibrosis (CF) continues to challenge scientists. There is growing evidence that increases in protease activity may be central to the pathogenesis of this lung disease. A team of scientists at the University of Alabama measured a common protease called MMP-9 in CF patients whose condition is stable and compared it with healthy volunteers. Previous studies have shown increases in MMP-9 in CF patients in the throes of an acute pulmonary episode. In the latest study, scientists at the University of Alabama in Birmingham reported that MMP-9 levels were also higher than normal in CF patients with no active airway inflammation. The findings may point the way to new therapeutic agents that work to reduce pathological changes.

In other studies in the latest issue of Molecular Medicine, a team of Brazilian scientists tested the activity of a novel angiotensin converting enzyme (ACE) in thrombus formation in animals that were either hypertensive or not. They reported that the pharmacological activation of the ACE2 receptor with the experimental ligand reduced platelet attachment to vessels and thrombus formation. These results suggest that this could be a potential lead compound for the treatment of thrombogenic diseases.

Other findings in the journal include a pivotal discovery of immune regulation of cancer cells, an endogenous factor that works in wound healing, a gene therapy study on Fabry Disease, a study on the immunological properties at work in Celiac disease, and a new molecular fingerprint of lung injury.

Molecular Medicine is published by The Feinstein Institute for Molecular Research. The peer-reviewed journal strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. The journal, a bimonthly publication, serves as a forum through which scientists and researchers can communicate recent discoveries to a multi-disciplinary, international audience interested in understanding and curing disease.

To listen to the latest podcast on these studies visit www.molmed.org/podcast.html.

###

Read the full story at http://www.prweb.com/releases/Molecular-Medicine/cystic-fibrosis/prweb4017864.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Molecular marker could help spot pancreatic cancer early
2. Molecular discovery points to new therapies for brain tumors
3. USC researchers discover new molecular subtype of brain cancer
4. The Association for Molecular Pathology celebrates ruling in DNA patent case
5. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
6. SNMs Conjoint Mid-Winter Meetings continue to advance molecular imaging
7. Molecular pathways linked to sex, age affect outcomes in lung cancer
8. Ground Breaking Molecular Diagnostics Business Appoints New CEO
9. Select Topics in ALL: Molecular Characterization, Approaches to CNS Disease, and Post-remission Transplantation
10. Scientists show how molecular switch helps pancreatic cancer beat drugs
11. News from the Latest Issue of Molecular Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
News from Molecular Medicine
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... DC (PRWEB) , ... May 26, 2016 , ... There ... National Hot Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight ... dogs, 63 percent say grilling is their favorite way to cook a hot dog, ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... discovery of thousands of defective respirators, according to court documents and SEC filings. ... of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... ... On Memorial Day, Hope For Heroes and USA Medical Card will ... country. The nonprofit Hope For Heroes partnered with the leading provider of free ... military veterans, as well as police, firemen, and EMS professionals across the country, and ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: